Investigating the Relationship between Serum Level of s-Met (Soluble Hepatic Growth Factor Receptor) and Preeclampsia in the First and Second Trimesters of Pregnancy

Introduction. Preeclampsia (PE) is an important cause of mortality and morbidity for mothers, fetuses, and the newborns. Placenta plays a pivotal role in pathogenesis of PE. Hepatic growth factor (HGF) is a cytokine expressed by the mesenchymal stalk of placental villi during pregnancy and assumes a paracrine role in trophoblasts which express its receptor (c-MET). In the present study, we investigate the diagnostic value of s-Met (the soluble form of the receptor) in the first and second trimesters of pregnancy for early diagnosis of preeclampsia. Method and Materials. This is a case-control study conducted on 95 pregnant women. The serum level of s-Met was measured in the first and second trimesters, and the participants were followed until delivery. 44 individuals with preeclampsia (the case group) and 51 individuals without preeclampsia (the control group) were evaluated. Results. Serum level of s-Met in preeclamptic participants was lower than that of the control group in both the first and the second trimesters (P<0.0001). In addition, serum levels of s-Met were significantly lower during the first and second trimesters in patients with early, severe preeclampsia compared to those with late, mild preeclampsia (P<0.0001). The sensitivity and specificity of s-Met in the first and second trimesters were, respectively, (83%, 94%) and (77%, 94%) for early preeclampsia and (88%, 92%) and (86%, 98%) for severe preeclampsia. Conclusion. Considering our findings, serum level of s-Met may be used as a predictive factor for early detection of preeclampsia. Further research is required to corroborate the functional and therapeutic value of s-Met in preeclampsia.

Download Full-text

Elevated Serum Level of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Correlates with Stage of Chronic Lymphocytic Leukemia and Resistance to Treatment

Blood ◽

10.1182/blood.v112.11.4172.4172 ◽

2008 ◽

Vol 112 (11) ◽

pp. 4172-4172

Author(s):

Bulat Bakirov ◽

Anastasiya Sgibneva ◽

Akhat Bakirov

Keyword(s):

Growth Factor ◽

High Risk ◽

Serum Level ◽

Serum Levels ◽

Lymphocytic Leukemia ◽

Control Group ◽

Vascular Endothelial ◽

Fibroblast Growth ◽

High Risk Disease ◽

Endothelial Growth Factor

Abstract Background: B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in western world with an incidence of 3,36/100,000 in European males. It is characterized by a clonal growth of long lived, slowly proliferating mature B lymphoid cells in the bone marrow (BM), peripheral blood (PB), and lymphoid tissues. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) is a pleiotropic cytokine that plays a role in hematopoiesis and apoptosis. Angiogenesis may have a role in a pathophysiology of leukemias and antiangiogenesis therapy could have an anticancer effect. Aim: analyze the clinical significance of serum levels of angiogenic factors and how it’s correlate with clinical stage and survival in patients with B-CLL Methods: the enzyme-linked immunosorbent assays (ELISAs) for VEGF and bFGF were performed in 78 CLL patients and 29 healthy person as a control group. The patients was divided on low-risk disease (44 patients) and high-risk disease (34 patients). Results: VEGF and bFGF serum levels were significantly increased in patient with high-risk disease, the median serum VEGF level was 185.66 pg/ml, compared with 72.67 pg/ml in patient with a low-risk and in control, it was 48.62 pg/ml. The difference in the VEGF levels was significant for the comparison between low- and high-risk disease (p<0.001). VEGF levels correlate with high white blood cell/lymphocyte counts, short period of time to begin treatment, disease progression, lymphocyte doubling time and worse answer to chemotherapy. No significant increase was found in bFGF serum level between low- and high-risk disease (34.06 pg/ml and 35.84 pg/ml, respectevely), but between patient and control group it was differences in serum level of bFGF (34.85 pg/ml and 7.77 pg/ml, respectively) (p<0.001). Conclusion: as we found, serum levels of bFGF and VEGF were significantly higher in the patients with B-CLL than in controls. High serum level of VEGF and bFGF associated with poor prognosis and worse answer on treatment. In summary, our data suggest that angiogenic factors play a significant role in the leukemic process and may suggest novel therapeutic approaches in B-CLL.

Download Full-text

Serum Level of a Soluble Form of Endoglin (CD105) is Decreased after Goeckerman’s Therapy of Psoriasis

Acta Medica (Hradec Kralove Czech Republic) ◽

10.14712/18059694.2016.19 ◽

2011 ◽

Vol 54 (2) ◽

pp. 59-62 ◽

Cited By ~ 2

Author(s):

David Pohl ◽

Ctirad Andrýs ◽

Lenka Borská ◽

Zdeněk Fiala ◽

Květa Hamáková ◽

...

Keyword(s):

Serum Level ◽

Blood Donors ◽

Uv Light ◽

Coal Tar ◽

Severity Index ◽

Serum Levels ◽

Soluble Form ◽

Control Group ◽

Angiogenic Activity ◽

Pasi Score

Background. Goeckerman’s therapy (GT) of psoriasis is based on daily application of pharmacy grade coal tar on affected skin with subsequent exposure to UV light. Disturbances in angiogenic activity are characteristic for the immunopathogenesis of psoriasis. The aim of study was to evaluate the influence of GT of psoriasis on proinflammatory and angiogenic activities expressed as changes in levels of endoglin (CD105). Methods. Serum levels of a soluble form of endoglin were measured in peripheral blood samples of 38 patients with psoriasis before and after therapy. Sixty three otherwise healthy blood donors serve as a control group. The efficacy of GT was expressed as changes in Psoriasis Area and Severity Index (PASI). Results. PASI score was significantly diminished by GT (p<0.001). Serum levels of soluble CD105 were significantly diminished after GT. The serum level of soluble CD105 dropped from 7.85 ± 2.26 ng/ml before therapy to 7.01 ± 1.71 ng/ml after therapy (p= 0.0002). Compared to serum levels of soluble CD105 in healthy blood donors, serum levels of soluble CD105 in patients before GT were significantly higher (p<0.001) and remained elevated after therapy (p<0.001). Angiogenic activity expressed as serum endoglin is diminished in patients with psoriasis treated by GT.

Download Full-text

Yolk sac–embryo distance in correlation with soluble form of vascular endothelial growth factor levels in pregnancy with potentially reserved evolutivity

Medical Ultrasonography ◽

10.11152/mu-1504 ◽

2018 ◽

Vol 20 (4) ◽

pp. 487

Author(s):

Carmen Elena Bucuri ◽

Razvan Ciortea ◽

Doru Diculescu ◽

Andrei Malutan ◽

Radu Mocan-Hognogi ◽

...

Keyword(s):

Growth Factor ◽

First Trimester ◽

Yolk Sac ◽

Soluble Form ◽

Control Group ◽

Case Group ◽

Crown Rump Length ◽

Low Level ◽

First Trimester Pregnancy ◽

Endothelial Growth Factor

Aims: Embryonic demise is a frequent complication of the first trimester pregnancy. The purpose of this study was to evaluate the correlation between a serum biomarker, the soluble form of the vasculo-endothelial growth factor (sFlt-1) and the distance between the yolk sac (YS) and embryo (DYSE), determined by ultrasonography.Material and methods: The study was a prospective case-control study that included 2 groups of patients – the control group with 81 first-trimester pregnancies in evolution and the case group with 89 first-trimester pregnancies with a potentially reserved evolutivity.Results: A correlation between the serum level of sFlt-1 and DYSE in embryos with crown-rump length (CRL) greater than 5 mm was identified, showing that a DYSE ≤3 mm correlates with a low level of sFlt-1 (p<0.05) and a DYSE> 4 mm correlates with an increased level of sFlt-1 (p<0.05).Conclusions: A low level of sFlt-1 associated with a distance between the embryo and yolk sac of small dimensions, respectively <3 mm, correlates with an increased rate of non-viable embryos. This correlation between an ultrasound and a serum parameter is of great value and brings important information about the viability of firsttrimester pregnancies.

Download Full-text

Serum levels of growth factors in patients with urinary bladder cancer

Turkish Journal of Biochemistry ◽

10.1515/tjb-2016-0129 ◽

2017 ◽

Vol 42 (5) ◽

Author(s):

Şölen Himmetoğlu ◽

Mustafa Bilal Tuna ◽

Eylem Efe Koç ◽

Süleyman Ataus ◽

Yildiz Dincer

Keyword(s):

Bladder Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Serum Level ◽

Urinary Bladder ◽

Urinary Bladder Cancer ◽

Serum Levels ◽

Control Group ◽

Her 2 ◽

Epidermal Growth

AbstractBackground:Altered signalling of human epidermal growth factor receptor-2 (HER-2/neu), insulin-like growth factor 1 (IGF-1) and epidermal growth factor (EGF) have been shown to play important role in tumor development and progression in various cancers. Their serum levels may be reliable indicator for diagnosis and progression of cancer.Objective:To examine the serum levels of soluble HER-2/neu (sHER-2/neu), IGF1 and EGF in patients with urinary bladder cancer (UBC).Material and methods:Serum levels of sHER-2/neu, IGF1 and EGF were measured by enzyme-linked immune assay in newly diagnosed, untreated patients with UBC.Results:In the patient group, sHER-2/neu level was found to be increased, IGF1 level was found to be decreased in comparison to those in the control group. Although serum level of sHER-2/neu was lower in the patients with Ta stage than that in the patients with T1 and T2 stages, this difference was not at a statistically significant level.Conclusion:Serum level of sHER-2/neu is increased in patients with UBC. Despite the lack of a significant association between sHER-2/neu level and pathological pT stage, sHER-2/neu may be a promising marker for UBC but IGF-1 and EGF have not such a potential.

Download Full-text

Serum level of stem cell factor and its soluble receptor in aspirin-exacerbated respiratory disease

Immunotherapy ◽

10.2217/imt-2019-0042 ◽

2019 ◽

Vol 11 (15) ◽

pp. 1283-1291 ◽

Cited By ~ 2

Author(s):

Rasoul Nasiri Kalmarzi ◽

Aida Foroutan ◽

Mohammad Abdi ◽

Pedram Ataee ◽

Ali Jalili ◽

...

Keyword(s):

Stem Cell ◽

Serum Level ◽

Stem Cell Factor ◽

Growth Factor Receptor ◽

Serum Levels ◽

Case Group ◽

Soluble Receptor ◽

Serum Samples ◽

Inflammatory Processes ◽

Severity Of The Disease

Aim: Stem cell factor (SCF) may be associated with inflammatory processes leading to aspirin-induced asthma. This study evaluated the relationship between serum level of SCF and its soluble receptor with aspirin-induced asthma. Methods & materials: Twenty-five patients and 25 healthy controls were enrolled in this study. The concentration of SCF and mast/stem cell growth factor receptor (C-kit) was determined in serum samples. Spirometry and rhinometry were performed to determine the severity of the disease. p < 0.05 were considered significant. Results: The serum levels of SCF and C-kit receptor were significantly higher in the case group. The serum SCF and C-kit level had a significant positive correlation with the severity of asthma, disease duration and nasal obstruction. Conclusion: Our findings suggest that SCF and C-kit receptors have a direct effect on the severity of aspirin-induced asthma.

Download Full-text

Comparative study between serum level of hepatocyte growth factor and CA-125 in patients with suspicious malignant adnexal masses

International Journal of Reproduction Contraception Obstetrics and Gynecology ◽

10.18203/2320-1770.ijrcog20164631 ◽

2016 ◽

Vol 6 (1) ◽

pp. 38

Author(s):

Ziad Mansour Ahmed ◽

Helmy Helmy Abdel Satar ◽

Moyassar Ahmed Zaki ◽

Hassan Mansour Hassan

Keyword(s):

Ovarian Cancer ◽

Growth Factor ◽

Serum Level ◽

Hepatocyte Growth Factor ◽

Serum Levels ◽

Ca 125 ◽

Control Group ◽

Ovarian Carcinomas ◽

Adnexal Masses ◽

Hepatocyte Growth

Background: Hepatocyte growth factor has been described to be increased in different cancers. The aim of the present study is to evaluate as a screening marker the‏ serum level of Hepatocyte growth factor among suspicious adnexal masses as compared to serum levels of CA125.Methods: The present study included 80 female patients who are admitted to the Gynecology unit in Elshatby Maternity University Hospital divided into two groups. Forty patients with benign gynecological conditions (control group) and 40 patients with suspicious malignant adnexal masses (cases group). Preoperative blood samples were withdrawn from all patients of both cases and control group to assess the level of serum hepatocyte growth factor (HGF) and serum cancer antigen 125 (CA 125). Both were quantified using ELISA technique.Results: Out of the 40 cases with suspicious malignant adnexal masses, 35 had ovarian cancer while five only were borderline. Patients with ovarian carcinomas had significantly higher preoperative HGF and CA 125 serum levels than patients with borderline pathology. Patients with borderline tumors had a significantly higher serum HGF and CA 125 levels than patients with benign gynecological conditions in control group.Conclusions: HGF in serum was elevated in 71% of patients with suspicious malignant adnexal masses proved to be ovarian cancer by histopathology using a quantitative ELISA. HGF can be used as a screening tool for ovarian cancer.

Download Full-text

On the Relationship Between Serum Level of Interleukin-33 with Allergic Rhinitis and Its Severity in Children

Iranian Journal of Pediatrics ◽

10.5812/ijp.105094 ◽

2021 ◽

Vol In Press (In Press) ◽

Author(s):

Marzieh Heidarzadeh Arani ◽

Sara Nikafarin ◽

Hamidreza Gilasi

Keyword(s):

Allergic Rhinitis ◽

Serum Level ◽

Serum Levels ◽

Study Data ◽

High Serum ◽

Th2 Cells ◽

Control Group ◽

Case Group ◽

Interleukin 33 ◽

Pediatric Clinic

Background: T helper type 2 (Th2) cells are critical cellular elements in allergic rhinitis. Interleukin-33 (IL-33) produces Th2-related cytokines and binds to the ST2 receptors. This is expressed strongly in mastocytes and discerningly in Th2 cells. Through Th2 cells, IL-33 may also have partly involved in immune responses. Objectives: This study aimed to measure the IL-33 serum levels in children suffering from allergic rhinitis and investigate its relationship with the disease. Methods: This case-control study was conducted on a population with the age range of 7-18 years, who referred to the Pediatric Clinic of the Shahid Beheshti Hospital in Kashan, Iran, in 2017. The study sample encompassed 57 patients with allergic rhinitis (case group) and 57 subjects with no allergic rhinitis (control group). The ELISA assay was used to measure the serum level of IL-33 in the case and control groups. Allergic rhinitis was diagnosed by a pediatric immunologist considering the patient’s history and the guidelines set out by the Allergic Rhinitis and its Impact on Asthma (ARIA). All study data were analyzed with SPSS software version 22. Results: There were significant differences between the two groups in terms of age (P = 0.001), gender (P = 0.0144), family history of atopy (P < 0.001), symptoms duration (P < 0.001), and comorbidities (e.g., atopic dermatitis and asthma) (P < 0.001). Furthermore, compared to the control group, the case group exhibited significantly higher IL-33 serum levels (P < 0.001). Conclusions: The high serum levels of IL-33 exhibited in patients with allergic rhinitis indicate its involvement in the pathogenesis of the concerned disease.

Download Full-text

Changes of Serum TNF-α in Acute Pancreatitis Patients and Its Clinical Significance

Advanced Emergency Medicine ◽

10.18686/aem.v4i4.11 ◽

2015 ◽

Vol 4 (4) ◽

pp. 33

Author(s):

Wenrui Yang

Keyword(s):

Acute Pancreatitis ◽

Serum Level ◽

Clinical Significance ◽

Severity Of Illness ◽

Serum Levels ◽

Enzyme Linked Immunosorbent Assay ◽

Control Group ◽

Case Group ◽

Tnf Α ◽

Α Level

Objective: The aimed of this study is to investigate the changes in serum levels of tumor necrosis factor (TNF-α) in the patients with acute pancreatitis treated with octreotide and its clinical significance. Method: Total of 65 patients of acute pancreatitis were selected as a case study, in which 30 patients with mild acute pancreatitis (MAP) and 35 severe acute pancreatitis (SAP) patients were treated with octreotide. 60 healthy subjects as control group and 65 case group was subjected to performed double antibody sandwich enzyme-linked immunosorbent assay (ELISA) to detect the serum levels of TNF-α. Results: The serum TNF-α level in the case group was (12.67 ± 3.45) pg/mL and the control group was (1.56 ± 0.57) pg/mL. Case group was significantly higher than control group (p < 0.05). Serum level of acute pancreatitis (AP) before treatment was (8.96 ± 2.12) pg/mL. After treatment, SAP group was (17.34 + 4.56) pg/mL, MAP group was significantly lower than SAP group, and the difference was statistically significant (p < 0.05). Conclusion: The serum levels of TNF-α in patient with acute pancreatitis were significantly higher than those of normal healthy people, and their serum level was closely related to the severity of illness.

Download Full-text

Clinical, Prognostic and Possible Therapeutic Relevance of Angiogenesis in Non-Hodgkin’s Lymphoma.

Blood ◽

10.1182/blood.v110.11.3583.3583 ◽

2007 ◽

Vol 110 (11) ◽

pp. 3583-3583

Author(s):

Leina Y. Etto ◽

Emilio C.A. Lacerda ◽

Otavio C.G. Baiocchi ◽

Vanderleia C. Silva ◽

Maria Aparecida Dalboni ◽

...

Keyword(s):

Growth Factor ◽

Serum Level ◽

International Prognostic Index ◽

Prognostic Index ◽

Serum Levels ◽

Biological Behavior ◽

Control Group ◽

Serum Samples ◽

Tumor Load ◽

Hodgkin's Lymphomas

Abstract Considering that angiogenesis may have importance in the pathogenesis of non-Hodgkin’s lymphomas (NHL), the aims of this study were to correlate hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF) serum levels and microvessel density (MVD) with cell origin, biological behavior, tumor load and prognosis in NHL. Materials and methods: Eighty-seven consecutive previously untreated NHL patients had serum samples collected and were included in the study. Thirty-seven (42%) of them also had additional serum follow-up samples. Control group was composed by ten healthy blood donors. HGF, VEGF and FGF serum levels were determined by ELISA. MVD was measured by CD34 staining in patients with available paraffin blocks. Results: HGF mean serum level was significantly higher in both early and advanced NHL Ann Arbor stages when compared to control group. HGF was also significantly higher in both aggressive and indolent NHL when compared to control group. Furthermore, mean serum level of HGF in aggressive NHL was significantly higher than in indolent NHL. Regarding International Prognostic Index (IPI), mean serum levels of HGF at diagnosis was significantly higher for patients with IPI > 2 when compared to IPI <=2. FGF mean serum level was also significantly higher in early and advanced NHL stages when compared to controls. We also observed that FGF mean serum level was significantly higher in indolent NHL when compared to control group. Regarding VEGF, serum levels were significantly higher in aggressive NHL when compared to control group. Sequential analyses of HGF, VEGF and FGF serum levels in NHL showed that serum HGF and VEGF levels decreased significantly after 6 months of treatment completion. When we analyzed MVD, no associations between patient’s groups were found, even when stage, biologic behavior or cell origin were taken into account. We did not find correlation among MVD and serum levels of HGF, VEGF and FGF at diagnosis either. Conclusions: Our findings suggest that HGF seems to play an important role in NHL pathogenesis because: its serum level is associated to tumor load and aggressiveness; it can be correlated to treatment response. In face of these results, we could suggest that HGF is a potential target for therapeutic intervention in NHL.

Download Full-text